Inhibrx Biosciences expanded its loan agreement with Oxford Finance, increasing the total credit facility to $500 million. The company received an immediate $100 million upfront payment (Term C Loan) and can request up to an additional $225 million (Term D Loan) at the lenders' discretion. To secure the initial funding, Inhibrx issued warrants to buy roughly 21,500 shares at an exercise price of $93.21 per share.

View Full Filing (SEC EDGAR)

View all Form 8-K filings

FAQ

Who are the top institutional investors holding INHIBRX BIOSCIENCES INC (INBX)?

Major stakeholders currently include Perceptive Advisors LLC ($97.0M), Viking Global Investors LP ($96.7M), Morgan Stanley ($84.9M). Based on the latest 13F filings, there are a total of 138 tracked investment funds and institutions maintaining positions in INBX.

What is the overall institutional sentiment toward INBX recently?

Institutional sentiment appears Bearish (Net Selling). During the most recent reporting quarter, the stock experienced a net outflow of $221.4M, driven by 71 managers accumulating shares while 64 reduced their exposure.

Which institutions have been selling or reducing their INBX positions?

In the latest period, 38 funds trimmed their holdings, and 26 managers completely exited their positions. The aggregate reported sell value was $512.6M.

Are there any notable investors adding INBX to their portfolios?

Yes, buying activity remains notable. 17 institutions opened new positions in {ticker}, and 54 existing holders added to their shares. The total reported buy value for the quarter amounted to $361.9M.